Janus Pharmaceuticals

Janus Biotherapeutics is a clinical-stage biotechnology company dedicated to developing novel, orally available small molecule inhibitors for the treatment of autoimmune diseases. The company's primary focus is on targeting Toll-like receptors (TLRs), specifically TLR7, TLR8, and TLR9, which play a critical role in the innate immune system's aberrant activation in conditions like lupus and rheumatoid arthritis. Janus gained significant industry attention through a major collaboration with Roche in 2015 to advance its lead TLR inhibitor programs. By leveraging its deep expertise in TLR biology, the company aims to provide differentiated oral therapies that address high unmet medical needs in chronic inflammatory disorders. Its approach focuses on achieving potent, selective inhibition to modulate the immune response without systemic safety concerns.